MaxCyteMXCT +5.51%62 Current Ratio is 12.04 as of Mar. 2026, which is 12% above its 10-year median of 10.77. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, MaxCyte ranks better than 95.55% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. MaxCyte's current ratio for the quarter that ended in Mar. 2026 was 12.04.
MaxCyte has a current ratio of 12.04. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for MaxCyte's Current Ratio or its related term are showing as below:
MXCT'
s Current Ratio Range Over the Past 10 Years
Min: 2.62 Med: 10.77 Max: 21.43
Current: 12.04
During the past 13 years, MaxCyte's highest Current Ratio was 21.43. The lowest was 2.62. And the median was 10.77.
MXCT's Current Ratio is ranked better than 95.55% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs MXCT: 12.04
MaxCyte (NAS:MXCT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
MaxCyte Current Ratio Related Terms
MaxCyte Current Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, NNOX, SNWV: Current Ratio Comparison
For the Medical Devices subindustry, MaxCyte's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Current Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Current Ratio of 12.04 as of Mar. 2026. This is 12% above median its historical median of 10.77. Over the past decade, MaxCyte's Current Ratio has ranged from 2.62 to 21.43. According to the industry distribution chart, MaxCyte ranks #38 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 4.4%.
Is MaxCyte's Current Ratio too high?
MaxCyte's current Current Ratio of 12.04 is 12% above median its 10-year median of 10.77. Over the past 10 years, this metric has ranged from a low of 2.62 to a high of 21.43. The Medical Devices & Instruments industry median Current Ratio is 2.49. MaxCyte's value of 12.04 is 384.5% above this industry median. Based on the distribution chart, MaxCyte ranks #38 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Current Ratio compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #38 out of 854 companies for Current Ratio. This places MaxCyte in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. MaxCyte's value of 12.04 is 384.5% above this benchmark. Historically, MaxCyte's own Current Ratio has ranged from 2.62 to 21.43 over the past decade. While the company's 10-year median is 10.77 vs. the industry median of 2.49, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Current Ratio of 12.04 is 384.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Current Ratio is 12.04, which is 12% above median its own 10-year median of 10.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.34 — trading 47.9% below its estimated fair value. The current Current Ratio is 12.04, which is 12% above median its 10-year median of 10.77 and 384.5% above the Medical Devices & Instruments industry median of 2.49. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current Current Ratio is 12.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.34 is trading 47.9% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Current Ratio: 12.04 (12% above median its 10-year median of 10.77)
GF Value™: $2.57 vs. price of $1.34 (47.9% below fair value)
Industry Position: 384.5% above the Medical Devices & Instruments median (#38 of 854)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
